Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

  • Technology appraisal guidance
  • TA857
  • Published: 

Tools and resources

Resource impact

Guidance into practice